This study is testing a new radioactive imaging medicine called 64CU-DOTA-ECL1i. It aims to see how well this medicine can help doctors visualize atherosclerosis (a condition where plaque builds up inside your arteries) in the carotid and femoral arteries. The study is looking for healthy volunteers aged 18-40, and patients aged 50-89 with known carotid artery atherosclerosis who may or may not be having surgery. The main goal is to evaluate the imaging characteristics of 64CU-ECL1i. The current recruitment status is unclear, but the study plans to enroll 100 participants.

Study design

This interventional study plans to enroll 100 participants. It involves two groups: one for those having surgery and healthy volunteers, and another for those not having surgery.

What's involved

If you are in Group 1, you will have one imaging session lasting about 60 minutes. If you are in Group 2, you will have two imaging sessions 7-14 days apart.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, evaluation of imaging characteristics, is measured at 1 or 2 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.